Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications
| Autor: | Cindy J Bednasz, Gene D. Morse, Charles S. Venuto, Qing Ma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug Substance-Related Disorders media_common.quotation_subject Hepatitis C virus Pharmaceutical Science Disease Pharmacology medicine.disease_cause 030226 pharmacology & pharmacy Article 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Medicine Humans Pharmacology (medical) Drug Interactions Addiction treatment media_common business.industry virus diseases Antiretroviral therapy Hepatitis C 030104 developmental biology Anti-Retroviral Agents Liver Drug Therapy Combination business Methadone medicine.drug Buprenorphine |
| Popis: | There are many factors that can affect the pharmacokinetics (PK) of drugs. Pathophysiological changes from disease states can alter the mechanisms that control the PK of antiretrovirals (ARVs), direct-acting antivirals (DAAs) and addiction treatment medications. Drug-drug interaction pathways of certain ARVs and DAAs can be very complex, with agents being substrates, inhibitors or inducers of multiple metabolic and transporter pathways. Buprenorphine and methadone may be used in HIV and hepatitis C virus (HCV) - infected patients, and may also be affected by drug interactions. Current research is focused on novel PK analyses, which aim to describe the PK of agents within the organs that host the infection of interest, such as within hepatocytes during treatment for HCV. Modeling techniques allow for the prediction of drug PK in specific organs and the plasma compartment. This review will provide a summary of these areas while exploring PK considerations for ARVs, DAAs, and addiction treatment medications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|